On the public citation graph
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
0 signed · 315 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/bjs.10677openalex-snapshot
Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma
inferredcites →https://doi.org/10.1002/hep.29225openalex-snapshot
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey
inferredcites →https://doi.org/10.1016/j.jclinepi.2010.04.026openalex-snapshot
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
inferredcites →https://doi.org/10.1016/j.jhep.2016.05.044openalex-snapshot
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
inferredcites →https://doi.org/10.1016/s0140-6736(02)08649-xopenalex-snapshot
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32453-9openalex-snapshot
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(18)30207-1openalex-snapshot
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30165-2openalex-snapshot
Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
inferredcites →https://doi.org/10.1056/nejm199603143341104openalex-snapshot
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-snapshot
Sorafenib in Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1717002openalex-snapshot
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1915745openalex-snapshot
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1111/hepr.12464openalex-snapshot
Evidence‐based C linical P ractice G uidelines for H epatocellular C arcinoma: The J apan S ociety of H epatology 2013 update (3rd JSH‐HCC G uidelines)
inferredcites →https://doi.org/10.1111/hepr.13411openalex-snapshot
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
inferredcites →https://doi.org/10.1111/j.1872-034x.2007.00216.xopenalex-snapshot
Development of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan
inferredcites →https://doi.org/10.1111/tri.13391openalex-snapshot
Expanded living‐donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5‐5‐500 rule ‐ a retrospective study
inferredcites →https://doi.org/10.1159/000521665openalex-snapshot
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)
inferredcites →https://doi.org/10.1200/jco.2021.39.15_suppl.4093openalex-snapshot
A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival.
inferredcites →https://doi.org/10.3748/wjg.v12.i5.828openalex-snapshot
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4834019openalex-extracted
Cost-Effectiveness of the Clinical Management of Hepatocellular Carcinoma in Four Asian-Pacific Countries
inferred← citeshttps://doi.org/10.1002/ags3.12872openalex-snapshot
Liver resection in patients with a history of local ablation for hepatocellular carcinoma has the risk of poor survival and serosal invasion
inferred← citeshttps://doi.org/10.1002/ags3.70153openalex-snapshot
Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies
inferred← citeshttps://doi.org/10.1002/ags3.70177openalex-snapshot
Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies
inferred← citeshttps://doi.org/10.1002/aid2.13438openalex-snapshot
Safety of transcatheter arterial chemoembolization for hepatocellular carcinoma in older adults aged ≥ 85 years: A single‐institution retrospective preliminary study
inferred← citeshttps://doi.org/10.1002/cam4.5931openalex-snapshot
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
inferred← citeshttps://doi.org/10.1002/cam4.71066openalex-snapshot
Anti‐Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy
inferred← citeshttps://doi.org/10.1002/cam4.71171openalex-snapshot
Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study
inferred← citeshttps://doi.org/10.1002/cam4.71470openalex-snapshot
Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification
inferred← citeshttps://doi.org/10.1002/cam4.71506openalex-snapshot
Predictive Value of Serum Autotaxin for Hepatocellular Carcinoma Recurrence After Curative Radiofrequency Ablation
inferred← citeshttps://doi.org/10.1002/cam4.71616openalex-snapshot
Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy
inferred← citeshttps://doi.org/10.1002/cam4.71655openalex-snapshot
Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/cam4.71787openalex-snapshot
Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real‐World Data Based on a Health Claims Database
inferred← citeshttps://doi.org/10.1002/cam4.71812openalex-snapshot
Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation
inferred← citeshttps://doi.org/10.1002/cam4.72242openalex-snapshot
Prognostic Impact of Arterial Phase Hyperenhancement After Proton Beam Therapy for Untreated Solitary Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/cnr2.2101openalex-snapshot
Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1002/jcu.23879openalex-snapshot
Diagnostic Test Accuracy of Contrast‐Enhanced Ultrasound With Sonazoid for Assessment of Focal Liver Lesions: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/jgh3.70033openalex-snapshot
Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
inferred← citeshttps://doi.org/10.1002/jmri.29167openalex-snapshot
Comparative Performance of 2018 LI‐RADS versus Modified LIRADS ( mLI‐RADS ): An Individual Participant Data Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/jmri.29748openalex-snapshot
Current State of Evidence for Use of MRI in LI ‐ RADS
inferred← citeshttps://doi.org/10.1002/jmri.70447openalex-snapshot
Effect of 37°C Pre‐Warmed Versus Room Temperature Gadoxetic Acid Disodium Contrast Medium on Patient Comfort and Image Quality in Liver MRI : A Prospective, Double‐Blind, Self‐Controlled Before‐and‐After Study
inferred← citeshttps://doi.org/10.1002/wjs.70418openalex-snapshot
Worse Prognosis of Patients With Hepatocellular Carcinoma and Portal Vein Invasion Underestimated by Imaging
inferred← citeshttps://doi.org/10.1007/978-3-032-07072-2_9openalex-snapshot
Liver Transplantation for Malignancies
inferred← citeshttps://doi.org/10.1007/s00259-026-08143-3openalex-snapshot
Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis
inferred← citeshttps://doi.org/10.1007/s00261-023-04064-zopenalex-snapshot
Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s00330-026-12381-2openalex-snapshot
The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI
inferred← citeshttps://doi.org/10.1007/s00330-026-12387-wopenalex-snapshot
Bridging east and west: ancillary features and AFP to improve MRI diagnosis of ≤ 30 mm HCC
inferred← citeshttps://doi.org/10.1007/s00423-024-03474-xopenalex-snapshot
Preoperative predictors of very early recurrence in patients with hepatocellular carcinoma beyond the Milan criteria
inferred← citeshttps://doi.org/10.1007/s00535-025-02233-zopenalex-snapshot
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
inferred← citeshttps://doi.org/10.1007/s00535-025-02251-xopenalex-snapshot
Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s00535-025-02312-1openalex-snapshot
Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial
inferred← citeshttps://doi.org/10.1007/s00535-026-02380-xopenalex-snapshot
Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s00595-026-03331-yopenalex-snapshot
Postoperative liver function trajectories and risk factors after hepatectomy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s10147-024-02497-0openalex-snapshot
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2
inferred← citeshttps://doi.org/10.1007/s10147-024-02553-9openalex-snapshot
New predictors of microvascular invasion for small hepatocellular carcinoma ≤ 3 cm
inferred← citeshttps://doi.org/10.1007/s10147-025-02703-7openalex-snapshot
Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies
inferred← citeshttps://doi.org/10.1007/s10147-025-02898-9openalex-snapshot
Refining the role of liver transplantation as a curative treatment for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s10396-025-01564-xopenalex-snapshot
“Suspended ceiling sign”꞉ an unusual hemorrhagic complication following radiofrequency ablation for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s10620-025-08884-5openalex-snapshot
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s10637-024-01441-3openalex-snapshot
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
inferred← citeshttps://doi.org/10.1007/s10637-024-01470-yopenalex-snapshot
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s11523-023-01026-9openalex-snapshot
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s11604-024-01640-1openalex-snapshot
Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
inferred← citeshttps://doi.org/10.1007/s12072-024-10732-zopenalex-snapshot
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
inferred← citeshttps://doi.org/10.1007/s12072-025-10781-yopenalex-snapshot
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
inferred← citeshttps://doi.org/10.1007/s12072-025-10794-7openalex-snapshot
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
inferred← citeshttps://doi.org/10.1007/s12072-025-10875-7openalex-snapshot
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
inferred← citeshttps://doi.org/10.1007/s12328-023-01854-2openalex-snapshot
Laparoscopic hepatectomy for hepatocellular carcinoma in patients with hemophilia A and B: a report of two cases
inferred← citeshttps://doi.org/10.1007/s12328-023-01909-4openalex-snapshot
A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report
inferred← citeshttps://doi.org/10.1007/s12328-024-01938-7openalex-snapshot
Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy
inferred← citeshttps://doi.org/10.1007/s12328-024-01946-7openalex-snapshot
Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series
inferred← citeshttps://doi.org/10.1007/s12328-025-02266-0openalex-snapshot
Successful treatment of β-catenin-positive, immune checkpoint inhibitor-resistant tumor in a case of multicentric hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s13304-026-02773-wopenalex-snapshot
Additive value of oncological resectability criteria for predicting post-hepatectomy liver failure in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s13691-024-00683-5openalex-snapshot
A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response
inferred← citeshttps://doi.org/10.1007/s44178-026-00256-xopenalex-snapshot
Physicians’ perceptions of HCC conversion/downstaging therapy: a nationwide survey among tertiary hospital physicians in China
inferred← citeshttps://doi.org/10.1016/j.acra.2026.09.039openalex-snapshot
Diagnostic Performance of CEUS LI-RADS for Hepatocellular Carcinoma ≤ 30 mm in Chinese Expanded High-Risk Patients: A Multicenter Analysis
inferred← citeshttps://doi.org/10.1016/j.aohep.2026.102434openalex-snapshot
Hepatocellular carcinoma surveillance in MASLD: from cirrhosis-based screening to personalized risk stratification
inferred← citeshttps://doi.org/10.1016/j.asjsur.2023.10.042openalex-snapshot
Utilization of muscle area in an accurate prediction formula for renal function for patients with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.asjsur.2025.07.186openalex-snapshot
Survival outcome with liver resection versus percutaneous radiofrequency ablation in patients with 2–3 cm single hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.189016openalex-snapshot
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions
inferred← citeshttps://doi.org/10.1016/j.bbrc.2025.151431openalex-snapshot
Serum PKCδ is a useful biomarker to distinguish hepatocellular carcinoma from other gastrointestinal cancers
inferred← citeshttps://doi.org/10.1016/j.cld.2024.09.001openalex-snapshot
Surveillance for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clnesp.2024.06.055openalex-snapshot
Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.clnesp.2025.02.018openalex-snapshot
Cachexia is an independent predictor of mortality in patients with hepatocellular carcinoma on systemic targeted therapy
inferred← citeshttps://doi.org/10.1016/j.crad.2024.106784openalex-snapshot
Diagnostic performance of LR-5 based on hypointensity on Gd-EOB-DTPA–enhanced MRI in the hepatobiliary phase for sHCC using LI-RADS v2018 criteria
inferred← citeshttps://doi.org/10.1016/j.cson.2026.100127openalex-snapshot
Locoregional combined systemic therapies for unresectable hepatocellular carcinoma in the era of immunotherapy: a narrative review
inferred← citeshttps://doi.org/10.1016/j.diii.2026.04.007openalex-snapshot
Hepatobiliary MRI contrast agents: Properties, clinical applications and future directions
inferred← citeshttps://doi.org/10.1016/j.ejrad.2025.111979openalex-snapshot
Usefulness of linearly-decelerated injection (downslope) method in arterial-phase CT of liver in evaluation of hypervascular lesions compared with standard injection method
inferred← citeshttps://doi.org/10.1016/j.ejro.2026.100814openalex-snapshot
Utility of intracellular enhancement for improving hepatic lesion visibility at gadoxetic acid-enhanced hepatobiliary-phase MRI
inferred← citeshttps://doi.org/10.1016/j.ejso.2026.111977openalex-snapshot
Vessel co-option negatively affects survival in patients with advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.esmoop.2026.107771openalex-snapshot
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.gastha.2025.100634openalex-snapshot
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e38850openalex-snapshot
Machine learning model based on dynamic contrast-enhanced ultrasound assisting LI-RADS diagnosis of HCC: A multicenter diagnostic study
inferred← citeshttps://doi.org/10.1016/j.hpb.2026.08.2009openalex-snapshot
IHPBA 2026 global guideline for the management of hepatocellular carcinoma in resource-constrained healthcare settings
inferred← citeshttps://doi.org/10.1016/j.ijscr.2024.110591openalex-snapshot
Conversion hepatectomy after chemotherapy including nivolumab for multiple liver metastases of hepatoid adenocarcinoma of the stomach: A case report and literature review
inferred← citeshttps://doi.org/10.1016/j.jceh.2024.101474openalex-snapshot
Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies
inferred← citeshttps://doi.org/10.1016/j.jgo.2026.104151openalex-snapshot
Management of hepatocellular carcinoma in older patients – An overview
inferred← citeshttps://doi.org/10.1016/j.jhep.2026.03.004openalex-snapshot
Advances in the imaging of liver cancer
inferred← citeshttps://doi.org/10.1016/j.jhepr.2025.101509openalex-snapshot
Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.jhepr.2026.101988openalex-snapshot
Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.jncc.2026.04.002openalex-snapshot
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses
inferred← citeshttps://doi.org/10.1016/j.nut.2024.112440openalex-snapshot
Dysphagia risk evaluated by the Eating Assessment Tool-10 is associated with health-related quality of life in patients with chronic liver disease
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.107733openalex-snapshot
Traditional Chinese medicine and natural products in management of hepatocellular carcinoma: Biological mechanisms and therapeutic potential
inferred← citeshttps://doi.org/10.1016/j.radi.2025.102976openalex-snapshot
Usefulness of contrast injection methods with the implanted port system during dynamic hepatic computed tomography scan
inferred← citeshttps://doi.org/10.1016/j.rx.2024.05.004openalex-snapshot
Medios de contraste específicos para el estudio del hígado en resonancia magnética
inferred← citeshttps://doi.org/10.1016/j.rxeng.2024.05.002openalex-snapshot
Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging
inferred← citeshttps://doi.org/10.1016/j.suronc.2025.102328openalex-snapshot
Survival benefit of resectability determined by multiple surgeons in BCLC-C Stage: A single-center cohort study
inferred← citeshttps://doi.org/10.1016/j.ultrasmedbio.2025.11.007openalex-snapshot
Comparison of Contrast-Enhanced Ultrasound and CT/MRI in Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy
inferred← citeshttps://doi.org/10.1016/s0140-6736(25)01042-6openalex-snapshot
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
inferred← citeshttps://doi.org/10.1016/s0140-6736(25)01720-9openalex-snapshot
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
inferred← citeshttps://doi.org/10.1016/s0140-6736(26)00294-1openalex-snapshot
Perioperative immunotherapy for resectable hepatocellular carcinoma – Authors’ reply
inferred← citeshttps://doi.org/10.1016/s2468-1253(24)00434-5openalex-snapshot
Precision surgery for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41392-024-02072-zopenalex-snapshot
Liver diseases: epidemiology, causes, trends and predictions
inferred← citeshttps://doi.org/10.1038/s41416-025-03022-4openalex-snapshot
Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial
inferred← citeshttps://doi.org/10.1038/s41440-025-02222-yopenalex-snapshot
When should Lenvatinib be switched to an alternative medication in patients with HCC who do not exhibit reactive blood pressure elevation?
inferred← citeshttps://doi.org/10.1038/s41440-025-02234-8openalex-snapshot
Comment on “When should Lenvatinib be switched to an alternative medication in patients with HCC who do not exhibit reactive blood pressure elevation?”
inferred← citeshttps://doi.org/10.1038/s41571-023-00825-3openalex-snapshot
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
inferred← citeshttps://doi.org/10.1038/s41575-025-01143-yopenalex-snapshot
Improving surgical treatments for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41598-024-53199-6openalex-snapshot
The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL)
inferred← citeshttps://doi.org/10.1038/s41598-025-21373-zopenalex-snapshot
Serum tyrosine level is an independent factor for hepatocellular carcinoma development and mortality in patients with chronic liver disease
inferred← citeshttps://doi.org/10.1038/s43856-025-01303-wopenalex-snapshot
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
inferred← citeshttps://doi.org/10.1053/j.gastro.2024.11.014openalex-snapshot
To Look or Not to Look: A New Score for Stratifying Patients at Risk of Developing Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1093/bjr/tqaf123openalex-snapshot
Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
inferred← citeshttps://doi.org/10.1093/bjsopen/zrag007openalex-snapshot
Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus
inferred← citeshttps://doi.org/10.1093/jrr/rrae006openalex-snapshot
Albumin–bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1093/jrr/rraf026openalex-snapshot
Comparison of carbon ion radiotherapy and transarterial chemoembolization for unresectable solitary hepatocellular carcinoma >3 cm: a propensity score–matched analysis
inferred← citeshttps://doi.org/10.1093/jrr/rraf044openalex-snapshot
Tumor shrinkage after simultaneous proton therapy for multiple hepatocellular carcinomas
inferred← citeshttps://doi.org/10.1093/omcr/omae155openalex-snapshot
Hepatocellular carcinoma converted from atezolizumab and bevacizumab combination therapy: a case report
inferred← citeshttps://doi.org/10.1093/omcr/omag171openalex-snapshot
Selective cTACE to a segment target hepatocellular carcinoma lesion during atezolizumab plus bevacizumab therapy achieving delayed hypovascularization and shrinkage of non-target intrahepatic lesions: a case report
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000595openalex-snapshot
Quality of care in hepatocellular carcinoma—A critical review
inferred← citeshttps://doi.org/10.1097/hep.0000000000000595openalex-snapshot
Contrast-enhanced US for HCC: Finally out from the waiting list?
inferred← citeshttps://doi.org/10.1097/hep.0000000000001630openalex-snapshot
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria
inferred← citeshttps://doi.org/10.1097/hep.0000000000001781openalex-snapshot
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
inferred← citeshttps://doi.org/10.1097/js9.0000000000000914openalex-snapshot
Benefit of perioperative radiotherapy for hepatocellular carcinoma: a quality-based systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1097/js9.0000000000001943openalex-snapshot
Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials
inferred← citeshttps://doi.org/10.1097/js9.0000000000001950openalex-snapshot
Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis
inferred← citeshttps://doi.org/10.1097/js9.0000000000002302openalex-snapshot
Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1097/js9.0000000000004144openalex-snapshot
Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: A multicenter study
inferred← citeshttps://doi.org/10.1097/js9.0000000000004958openalex-snapshot
Recent advances in therapeutic and surgical approaches in locally advanced HCC: downstaging and neoadjuvant therapy
inferred← citeshttps://doi.org/10.1097/md.0000000000039289openalex-snapshot
Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/meg.0000000000002979openalex-snapshot
Lens culinaris-agglutinin-reactive fraction of alpha-fetoprotein is a prognostic biomarker in atezolizumab plus bevacizumab for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/meg.0000000000003080openalex-snapshot
Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study
inferred← citeshttps://doi.org/10.1097/meg.0000000000003158openalex-snapshot
Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study
inferred← citeshttps://doi.org/10.1097/meg.0000000000003256openalex-snapshot
Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort
inferred← citeshttps://doi.org/10.1097/meg.0000000000003285openalex-snapshot
Rapid ammonia normalization and long-term efficacy of rifaximin in patients with cirrhosis: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1097/ppo.0000000000000684openalex-snapshot
Hepatocellular Carcinoma—Southeast Asia Updates
inferred← citeshttps://doi.org/10.1097/xcs.0000000000001032openalex-snapshot
Proposal for Prognosis-Oriented Definition of Borderline Resectable Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1109/aiars63200.2024.00146openalex-snapshot
Design of E-Commerce with Machine Learning System Based on Neural Network
inferred← citeshttps://doi.org/10.1109/icdacai59742.2023.00147openalex-snapshot
A Recommendation Algorithm for Optimal Analysis of Audit Path
inferred← citeshttps://doi.org/10.1109/icdcot61034.2024.10515595openalex-snapshot
A Mining Algorithm for Grid Customer Information Based on Big Data
inferred← citeshttps://doi.org/10.1111/apt.18037openalex-snapshot
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
inferred← citeshttps://doi.org/10.1111/apt.70483openalex-snapshot
Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
inferred← citeshttps://doi.org/10.1111/cas.70456openalex-snapshot
NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2
inferred← citeshttps://doi.org/10.1111/hepr.13959openalex-snapshot
Significance of malnutrition defined with Global Leadership Initiative on Malnutrition criteria in patients with hepatocellular carcinoma after hepatic resection
inferred← citeshttps://doi.org/10.1111/hepr.14001openalex-snapshot
Prognostic significance of C‐reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
inferred← citeshttps://doi.org/10.1111/hepr.14014openalex-snapshot
Impact of the COVID‐19 pandemic on the number and short‐term outcomes in hepatectomy for hepatocellular carcinoma: Results from the Japanese National Clinical Database, 2018–2021
inferred← citeshttps://doi.org/10.1111/hepr.14085openalex-snapshot
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan
inferred← citeshttps://doi.org/10.1111/hepr.14089openalex-snapshot
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study
inferred← citeshttps://doi.org/10.1111/hepr.14139openalex-snapshot
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1111/hepr.14147openalex-snapshot
Comparable outcomes among etiologies in early‐stage hepatocellular carcinoma: Analysis of a nationwide registry in Japan
inferred← citeshttps://doi.org/10.1111/hepr.14193openalex-snapshot
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria
inferred← citeshttps://doi.org/10.1111/hepr.14194openalex-snapshot
The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.14208openalex-snapshot
Dynamic changes in the characteristics of hepatocellular carcinoma among Japanese patients: Increasing incidence of cases without liver fibrosis
inferred← citeshttps://doi.org/10.1111/hepr.14224openalex-snapshot
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
inferred← citeshttps://doi.org/10.1111/hepr.14233openalex-snapshot
Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
inferred← citeshttps://doi.org/10.1111/hepr.70008openalex-snapshot
Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.70011openalex-snapshot
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
inferred← citeshttps://doi.org/10.1111/hepr.70023openalex-snapshot
Association of Metabolic‐Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study
inferred← citeshttps://doi.org/10.1111/hepr.70027openalex-snapshot
Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study
inferred← citeshttps://doi.org/10.1111/hepr.70041openalex-snapshot
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
inferred← citeshttps://doi.org/10.1111/hepr.70047openalex-snapshot
Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication
inferred← citeshttps://doi.org/10.1111/hepr.70072openalex-snapshot
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.70099openalex-snapshot
Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.70102openalex-snapshot
Plasma Vascular Endothelial Growth Factor‐A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
inferred← citeshttps://doi.org/10.1111/hepr.70135openalex-snapshot
Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.70138openalex-snapshot
Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
inferred← citeshttps://doi.org/10.1111/hepr.70162openalex-snapshot
Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
inferred← citeshttps://doi.org/10.1111/hepr.70172openalex-snapshot
Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study
inferred← citeshttps://doi.org/10.1111/hepr.70187openalex-snapshot
Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.70215openalex-snapshot
Low Alpha‐Fetoprotein in Non‐Viral Early‐Stage Hepatocellular Carcinoma: Complementary Des‐Gamma‐Carboxyprothrombin
inferred← citeshttps://doi.org/10.1111/hepr.70228openalex-snapshot
Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study
inferred← citeshttps://doi.org/10.1111/hepr.70267openalex-snapshot
Rapid Intrasegmental Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Incidence, Imaging Features, and Clinical Outcomes
inferred← citeshttps://doi.org/10.1111/jgh.70280openalex-snapshot
Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study
inferred← citeshttps://doi.org/10.1111/jgh.70422openalex-snapshot
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
inferred← citeshttps://doi.org/10.1111/jjns.12619openalex-snapshot
Adjusting to living with chronic liver disease among patients who continue regular healthcare visits for hepatocellular carcinoma surveillance: A grounded theory study
inferred← citeshttps://doi.org/10.1111/liv.15753openalex-snapshot
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1111/liv.70217openalex-snapshot
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
inferred← citeshttps://doi.org/10.1111/liv.70734openalex-snapshot
Validation of Risk Models for Predicting Post‐SVR HCC in Real‐World Surveillance Across Global Geographic Regions
inferred← citeshttps://doi.org/10.1136/bmjgast-2025-002155openalex-snapshot
Diagnostic accuracy of surveillance tests for hepatocellular carcinoma in cirrhosis: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-080549openalex-snapshot
Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study
inferred← citeshttps://doi.org/10.1136/jitc-2024-010472openalex-snapshot
Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death
inferred← citeshttps://doi.org/10.1136/jitc-2025-013384openalex-snapshot
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
inferred← citeshttps://doi.org/10.1148/radiol.231656openalex-snapshot
Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis
inferred← citeshttps://doi.org/10.1159/000530079openalex-snapshot
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
inferred← citeshttps://doi.org/10.1159/000532023openalex-snapshot
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
inferred← citeshttps://doi.org/10.1159/000534304openalex-snapshot
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
inferred← citeshttps://doi.org/10.1159/000536211openalex-snapshot
Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000537686openalex-snapshot
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
inferred← citeshttps://doi.org/10.1159/000537897openalex-snapshot
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000537915openalex-snapshot
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
inferred← citeshttps://doi.org/10.1159/000538627openalex-snapshot
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
inferred← citeshttps://doi.org/10.1159/000539380openalex-snapshot
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy
inferred← citeshttps://doi.org/10.1159/000539381openalex-snapshot
Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000540801openalex-snapshot
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000541372openalex-snapshot
The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000542572openalex-snapshot
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial
inferred← citeshttps://doi.org/10.1159/000542577openalex-snapshot
Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000544051openalex-snapshot
The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
inferred← citeshttps://doi.org/10.1159/000546574openalex-snapshot
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
inferred← citeshttps://doi.org/10.1159/000546575openalex-snapshot
Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial
inferred← citeshttps://doi.org/10.1159/000547264openalex-snapshot
The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis
inferred← citeshttps://doi.org/10.1159/000548300openalex-snapshot
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis
inferred← citeshttps://doi.org/10.1159/000548516openalex-snapshot
Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study
inferred← citeshttps://doi.org/10.1159/000550100openalex-snapshot
Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi Panel
inferred← citeshttps://doi.org/10.1159/000550192openalex-snapshot
High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000550634openalex-snapshot
Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy
inferred← citeshttps://doi.org/10.1159/000550954openalex-snapshot
Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study
inferred← citeshttps://doi.org/10.1159/000551047openalex-snapshot
Oncological Outcomes and Treatment Strategies for Borderline Resectable Hepatocellular Carcinoma Based on the Oncological Resectability Classification
inferred← citeshttps://doi.org/10.1177/08465371241306297openalex-snapshot
Do Risk Factors for HCC Impact the Association of CT/MRI LIRADS Major Features With HCC? An Individual Participant Data Meta-Analysis
showing the first 200 of 296 · page through all 296
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.